Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects.
Ward, Timothy H
Tutt, A L
Cragg, M S
Illidge, Timothy M
AffiliationClinical and Experimental Pharmacology Laboratory, University of Manchester, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK.
MetadataShow full item record
AbstractRituximab is a chimeric anti-CD20 monoclonal antibody that has revolutionised the treatment of many B-cell malignancies, and is now increasingly being used in non-malignant conditions such as auto-immune disorders. Serum rituximab levels are highly variable in patients receiving similar 'standard' approved doses. Little is known regarding the factors that affect serum rituximab concentration and that in turn may influence clinical outcome. In order to provide a tool that may ultimately enable patient specific dosing of rituximab therapy, we have validated a reliable, robust ELISA for the quantitation of serum rituximab levels to provide accurate pharmacokinetic (PK) data that will guide the optimisation of rituximab dosing regimes. Extensive validation of the assay was performed in order to utilise the assay for clinical applications. The within and between day plate coating reproducibility was tested and proved a robust starting platform for the assay. The within day precision for the assay was determined using spiked serum samples and was shown to have a coefficient of variation (CV) of <10% with an accuracy between 91 and 125%. The between day precision (CV) was <25% with an accuracy between 95 and 109%. Dilution linearity and parallelism were demonstrated. Spike recovery for all concentrations and donors was shown to be within +/-15% on average, with a CV below 10%. This assay is highly accurate and reproducible in determining the levels of rituximab in spiked serum samples. It meets stringent acceptance criteria, is fit for purpose, and is currently being applied to several clinical trials incorporating rituximab in the treatment of lymphoma. This assay represents a useful tool for clinical application of this widely used therapeutic.
CitationValidation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. 2010: J Immunol Methods
JournalJournal of Immunological Methods
- Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
- Authors: Beum PV, Kennedy AD, Taylor RP
- Issue date: 2004 Jun
- Evaluation of a peptide ELISA for the detection of rituximab in serum.
- Authors: Blasco H, Lalmanach G, Godat E, Maurel MC, Canepa S, Belghazi M, Paintaud G, Degenne D, Chatelut E, Cartron G, Le Guellec C
- Issue date: 2007 Aug 31
- Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
- Authors: Stubenrauch K, Wessels U, Lenz H
- Issue date: 2009 May 1
- [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
- Authors: Tobinai K
- Issue date: 2002 Mar
- B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
- Authors: Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B
- Issue date: 2010 Mar